Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
Moodys
Johnson and Johnson
Boehringer Ingelheim

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Cisatracurium besylate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for cisatracurium besylate and what is the scope of freedom to operate?

Cisatracurium besylate is the generic ingredient in four branded drugs marketed by Accord Hlthcare, Anda Repository, Fresenius Kabi Usa, Hospira Inc, Jiangsu Hengrui Med, Nanjing King-friend, Sandoz Inc, Somerset Theraps Llc, and Abbvie, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cisatracurium besylate. Eight suppliers are listed for this compound.

Drug Prices for cisatracurium besylate

See drug prices for cisatracurium besylate

Recent Clinical Trials for cisatracurium besylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mahidol UniversityPhase 4
General Hospital of Ningxia Medical UniversityN/A
Medical University of GrazN/A

See all cisatracurium besylate clinical trials

Pharmacology for cisatracurium besylate
Synonyms for cisatracurium besylate
(1R-cis,1'R-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R-cis,1'R-cis)-Atracurium besylate
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfona
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate
(1R,2R,1'R,2'R)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R,2R,1'R,2'R)-atracurium besylate
(1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
51 W89
51W89
80YS8O1MBS
96946-42-8
AC1L1XZG
AC1Q22ND
AK546900
AKOS026750111
Atracurium besylate 1R-cis,1R'-cis form
Besilate de cisatracurium
Besilato de cisatracurio
C53H72N2O12.2(C6H5O3S)
C53H72N2O12.2C6H5O3S
CAS-64228-81-5
CCG-221271
CHEBI:3721
CHEMBL1200641
Cisatracurii besilas
Cisatracurium (besylate)
Cisatracurium besilate
Cisatracurium besilate (INN)
Cisatracurium besilate [INN]
Cisatracurium besilate, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium besylate (Nimbex)
Cisatracurium besylate (USAN)
Cisatracurium besylate [USAN:BAN]
Cisatracurium besylate [USAN]
Cisatracurium Besylate Preservative Free
Cisatracurium besylate, United States Pharmacopeia (USP) Reference Standard
cisatracurium besylate(usan)
cisatracurium dibenzenesulfonate
Cisatracurium for peak identification, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium for system suitability, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium-Kation
CS-2471
D00759
DB00565
EX-A2646
FT-0657467
HMS3715P04
HY-13596
Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1R-(1alpha,2alpha(1'R(sup *),2'R(sup *))))-
KS-00000FXO
LS-178337
MolPort-003-987-490
N769
NCGC00017127-01
Nimbex
Nimbex (TN)
Nimbex Forte
NIMBEX PRESERVATIVE FREE
Nimbium
s2113
SCHEMBL40669
SW222230-1
TL8006016
UNII-40AX66P76P component XXZSQOVSEBAPGS-DONVQRBFSA-L
UNII-80YS8O1MBS
UNII-Y78PS7MEDE component XXZSQOVSEBAPGS-DONVQRBFSA-L
W-60404
XXZSQOVSEBAPGS-DONVQRBFSA-L
Z2216208615
Paragraph IV (Patent) Challenges for CISATRACURIUM BESYLATE
Tradename Dosage Ingredient NDA Submissiondate
NIMBEX INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-12
NIMBEX PRESERVATIVE FREE INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-12
NIMBEX PRESERVATIVE FREE INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-04
NIMBEX INJECTABLE;INJECTION cisatracurium besylate 020551 2009-08-04

US Patents and Regulatory Information for cisatracurium besylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 203236-002 Mar 30, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Anda Repository CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 209132-001 Apr 24, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CISATRACURIUM BESYLATE PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 203182-002 Feb 26, 2015 AP RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 203183-001 Feb 26, 2015 AP RX No No   Start Trial   Start Trial   Start Trial
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for cisatracurium besylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995   Start Trial   Start Trial
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995   Start Trial   Start Trial
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995   Start Trial   Start Trial
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995   Start Trial   Start Trial
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Express Scripts
Merck
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.